A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
Latest Information Update: 24 Jul 2023
At a glance
- Drugs Oplunofusp (Primary)
- Indications COVID 2019 infections; Parainfluenza virus infections
- Focus Registrational; Therapeutic Use
- Acronyms RCT; STOP PIV
- Sponsors Ansun Biopharma
- 19 Jul 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 19 Jul 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 19 Jul 2023 Status changed from discontinued to recruiting.